|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2014
|
|
gptkbp:approvedBy
|
gptkb:United_States
|
|
gptkbp:ATCCode
|
A10BK03
|
|
gptkbp:CASNumber
|
864070-44-0
|
|
gptkbp:contraindication
|
gptkb:type_1_diabetes_mellitus
severe renal impairment
|
|
gptkbp:drugClass
|
SGLT2 inhibitor
|
|
gptkbp:eliminatedIn
|
urine
feces
|
|
gptkbp:form
|
gptkb:tablet
10 mg
25 mg
|
|
gptkbp:genericName
|
gptkb:empagliflozin
|
|
gptkbp:halfLife
|
12.4 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Jardiance
|
|
gptkbp:indication
|
gptkb:type_2_diabetes_mellitus
heart failure
|
|
gptkbp:KEGGID
|
D09917
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Boehringer_Ingelheim
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:mechanismOfAction
|
inhibits sodium-glucose co-transporter 2
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prescriptionStatus
|
Rx-only
|
|
gptkbp:PubChem_CID
|
10128638
11949646
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
urinary tract infection
hypotension
genital infection
ketoacidosis
|
|
gptkbp:UNII
|
GXT1PY3309
|
|
gptkbp:bfsParent
|
gptkb:Boehringer_Ingelheim
|
|
gptkbp:bfsLayer
|
6
|